Biochem/physiol Actions

Reversible: yes

Product competes with ATP.

Primary TargetGsk-3β

Target IC₅₀: 22 nM, 180 nM, and 100 nM against GSK-3β, Cdk1, and Cdk5, respectively

Cell permeable: yes

General description

A potent cell-permeable, reversible, and ATP-compatible inhibitor of glycogen synthase kinase-3β (IC₅₀ = 22 nM) and cyclin-dependent kinases (IC₅₀ = 180 nM for Cdk1 and 100 nM for Cdk5). Inhibits the proliferation of a large range of cells by arresting them in the G₂/M phase of the cell cycle. Inhibits Tau phosphorylation in vitro and in vivo at Alzheimer′s disease-specific sites. Also reported to inhibit the in vivo phosphorylation of DARPP-32 by Cdk5 on Thr⁷⁵.

A potent, reversible, and ATP-compatible inhibitor of GSK-3β (glycogen synthase kinase 3β), Cdk1 (cyclin-dependent kinase1) and Cdk5 (IC₅₀ = 22 nM, 180 nM, and 100 nM, respectively). Inhibits the proliferation of a large range of cells by arresting them in the G₂/M phase of the cell cycle. Inhibits Tau phosphorylation in vitro and in vivo at Alzheimer's disease-specific sites. Also reported to inhibit the in vivo phosphorylation of DARPP-32 by Cdk5 on Thr⁷⁵.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Bain, J., et al. 2003. Biochem. J. 371, 199.Leclerc, S., et al. 2000. J. Biol. Chem.276, 251.Hoessel, R., et al. 1999. Nat. Cell Biol. 1, 60.

Packaging

1 mg in Plastic ampoule

Packaged under inert gas

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Warning

Toxicity: Standard Handling (A)